Tempera named associate professor in the Gene Expression & Regulation Program at Wistar

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Italo Tempera was appointed associate professor in the Gene Expression & Regulation Program of The Wistar Institute Cancer Center.

Tempera is a molecular virologist with special expertise in the study of the Epstein Barr virus and how it regulates expression of its genes in the host cell during infection. Although EBV infection is very frequent and asymptomatic in most cases, in some individuals, especially those with a compromised immune system, it has a causative role in development of some types of cancer, including Burkitt’s lymphoma, nasopharyngeal carcinoma, and Hodgkin’s and non-Hodgkin’s lymphomas.

Research in the Tempera laboratory aims to disrupt the natural capacity of EBV to modulate its gene expression pattern as a new approach for treating EBV-associated cancers.

Tempera identified the main cellular factor that regulates the three-dimensional structure of the EBV genome and his laboratory focuses on the role of this factor, named CTCF, in the formation of loops in the virus DNA.

These loops allow distant segments of the genome to be in close proximity and regulate expression of EBV genes that are necessary for its life cycle within the cell. The team is also exploring how EBV chromatin loops are regulated by another cellular factor called PARP1. Given the role played by PARP1 in regulating cell metabolism after DNA damage, these studies could provide an exciting link between host cell metabolism and regulation of EBV chromatin structure.

The Tempera lab specializes in genomics techniques that allow them to study long-range interactions within chromatin, or the genetic material in which DNA and proteins are packed together to form chromosomes.

Tempera comes to Wistar from the Fels Institute for Cancer Research and Molecular Biology at the Lewis Katz School of Medicine of Temple University, where he established his lab in 2012 and was promoted to associate professor in 2017.

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login